Here are the 10-Q quarterly reports from Cryo-Cell International Inc. (CCEL) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow CCEL and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CCEL filings page.
Cryo-Cell International reported third-quarter revenue of $7,824,156, compared with $7,825,432 a year earlier, while net income rose to $1,270,490 from $749,408. For the nine months ended August 31, 2026, revenue was $23,283,386 versus $23,723,155 and net income was $1,872,184 versus $1,388,048.
Nine-month operating income was $4,156,206, down from $4,449,181, and operating cash flow was $3,639,507, compared with $4,197,793. Cash and cash equivalents totaled $1,425,663 at August 31, 2026. The revolving line of credit balance was zero, versus $2,300,000 at November 30, 2025.
Deferred revenue, including payments received before services are performed, totaled $63,972,130 at August 31, 2026; $9,719,618 was to be recognized over the next 12 months. Cryo-Cell reported receiving Duke's notice of termination of the license agreement effective May 17, 2025, and said it is unlikely to commercialize the licensed rights or otherwise obtain the agreement's benefits. The arbitration hearing concluded in late July 2026, and the company anticipates a final ruling by the end of calendar year 2026.
Cryo-Cell International (CCEL) filed its quarterly report, showing stable operations with softer topline. Revenue for the quarter ended August 31, 2025 was $7.83 million versus $8.07 million a year ago, as public banking and product sales remained small. Operating income improved to $1.90 million from $1.39 million on lower cost of sales and SG&A. Net income was $0.75 million ($0.09 diluted EPS) compared with $1.05 million ($0.13) last year.
For the nine months, revenue was $23.72 million versus $23.96 million; net income was $1.39 million ($0.17 diluted EPS) versus $2.26 million ($0.27). Interest expense weighed on results at $0.54 million in the quarter and $1.58 million year-to-date.
Deferred revenue tied to long-term storage contracts rose to $59.58 million ($9.74 million current), supporting future revenue recognition. Cash was $265,207 with $2.96 million in marketable securities. The company reported a stockholders’ deficit of $14.83 million driven by deferred revenue accounting and treasury stock. Debt included a $3.20 million line of credit and $8.39 million term note. As of October 15, 2025, 8,055,150 common shares were outstanding.